All In Biotech

Company · NVS

Novartis

Includes drugs filed under related and acquired sponsor names. Trials are searched under: Novartis Pharmaceuticals; Novartis.

Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

224

116 still marketed

Novel approvals

86

Approvals since 2021

85

Originals and new uses

Phase 3 trials

1,124

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

Drugs in development (59)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline
  • IanalumabVAY736, VAY736 AIPhase 318 trials

    Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome

  • GlucocorticoidsPhase 37 trials

    Novartis · VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease

  • PelacarsenTQJ230Phase 37 trials

    Novartis · Cardiovascular Disease and Lipoprotein(a), Atherosclerotic Cardiovascular Disease (ASCVD), Atherosclerotic Cardiovascular Disease

  • FUB523zigakibart, BION-1301Phase 36 trials

    Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)

  • PPV2323-valent Pneumococcal Polysaccharide Vaccine, lot 1Phase 36 trials

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Streptococcus Pneumoniae Infection, Pneumococcal Disease

  • KLU156Phase 34 trials

    Novartis · Uncomplicated Plasmodium Falciparum Malaria

  • PelabresibDAK539, CPI-0610Phase 34 trials

    Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)

  • 177Lu-PSMA-617Lutetium [177Lu] vipivotide tetraxetan, lutetium vipivotide tetraxetanPhase 33 trials

    Novartis · Prostatic Neoplasms, Prostatic Neoplasm, Metastatic Castration Resistant Prostate Cancer (mCRPC)

  • AbelacimabMAA868Phase 33 trials

    Anthos Therapeutics, Inc. · Atrial Fibrillation (AF), Stroke

  • Lutetium[177Lu] Oxodotreotidedotatate, 177Lu-DOTA0-Tyr3-OctreotatePhase 33 trials

    Sinotau Pharmaceutical Group · Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma

  • PacibekitugTOUR006, PAC001Phase 33 trials

    Tourmaline Bio, Inc., a Novartis Company · Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases

  • [68Ga]Ga-DOTA-TATEAAA501Phase 32 trials

    Novartis · Extensive Stage Small Cell Lung Cancer, Neuroendocrine Neoplasms

  • AAA817[225Ac]Ac-PSMA-617Phase 32 trials

    Novartis · Prostate Cancer

  • ARDTPhase 32 trials

    Novartis · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

  • ARPI: EnzalutamideARPI abirateronePhase 32 trials

    Novartis · Metastatic Castration Resistant Prostate Cancer (mCRPC), Prostate Cancer

  • NaporafenibLXH254, ERAS-254Phase 32 trials

    Novartis · Melanoma, Advanced or Metastatic NRAS-mutant Melanoma

  • GME751Phase 31 trial

    Novartis · Metastatic NSCLC

  • QMF149Phase 31 trial

    Novartis · Asthma

  • QVM149Phase 31 trial

    Novartis · Asthma

  • rapcabtagene autoleucelYTB323Phase 28 trials

    Novartis · Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV)

  • KAE609CipargaminPhase 25 trials

    Novartis · Uncomplicated Plasmodium Falciparum Malaria, Severe Malaria

  • luxdegalutamideJSB462, ARV-766Phase 24 trials

    Novartis · Prostatic Cancer, Castration-Resistant, Progressive Metastatic Castrate Resistant Prostate Cancer, Prostate Cancer Metastatic

  • MAS825ArumakimigPhase 24 trials

    Novartis · NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations, Still´s Disease, VEXAS Syndrome

  • DDY391Phase 23 trials

    Novartis · Moderate to Severe Psoriatic Arthritis, Sjögren's Disease

  • GIA632Phase 23 trials

    Novartis · Atopic Dermatitis, Non-segmental Vitiligo, Cutaneous Lichen Planus

Recruiting Phase 3 trials

Largest first.

Marketed drugs (116)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.